BPTH.OOTC
- Bio-Path Holdings, Inc.
报价延迟最少15分钟:2026/02/15 20:58 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.058 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.14/-1.37
|
|
企业价值
536.04K
|
| 资产负债 |
|
每股账面净值
-0.87
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||
|
||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition forany gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE. |
